Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

Abstract Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ve...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gema Miñana, Julio Núñez, Antoni Bayés‐Genís, Elena Revuelta‐López, César Ríos‐Navarro, Eduardo Núñez, Francisco J. Chorro, Maria Pilar López‐Lereu, Jose Vicente Monmeneu, Josep Lupón, Juan Sanchis, Vicent Bodí
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Oxford University Press 2020-02-01
coleção:	ESC Heart Failure
Assuntos:	PCSK9 Left ventricular ejection fraction Cardiac magnetic resonance ST‐segment elevation myocardial infarction
Acesso em linha:	https://doi.org/10.1002/ehf2.12533
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!